New Human Leukocyte Antigen (HLA) Antibody Formation and Creatinine Elevation With Abaloparatide in Kidney Transplant Recipient.

Swanson CM, Krohn K, Wiseman A, Rothman MS

JBMR plus21 Sept 2023Cited by 1 (Europe PMC)

PMID38130769PMCIDPMC10731105DOI10.1002/jbm4.10814PepBankPUB-38130769

Summary

A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall. Her kidney transplant regimen (mycophenolate mofetil 360 mg twice a day, tacrolimus 0.5 mg every morning and 0.5-1 mg every evening, prednisone 5 mg/day) and baseline creatinine (1.0-1.2 mg/dL) had been stable for several years. After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis. She had a good initial biochemical response to therapy. However, 5 months after abaloparatide initiation she was found to have a new elevation in serum creatinine (1.17 to 1.69 mg/dL) despite stable serum tacrolimus trough levels, and two new human leukocyte antigen (HLA) antibodies (anti-HLA antibodies detected to Cw7 and DP28). Abaloparatide was stopped due to concern for immunogenicity. There was no evidence of rejection on kidney biopsy and she was restabilized on her transplant regimen with a new baseline creatinine of 1.3-1.6 mg/dL. The patient was subsequently started on teriparatide 20 μg daily subcutaneous injections for 2 years with good biochemical response, significant improvement in bone mineral density, and stable transplant regimen without additional signs of immunogenicity or rejection. This is the first case report to raise concern about immunogenicity with abaloparatide in solid organ transplant recipients. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesEfficacy outcome
In a kidney transplant recipient, a good initial biochemical response occurred after abaloparatide initiation.
In plain wordsIn a kidney transplant recipient, a good initial biochemical response occurred after abaloparatide began.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableInitial biochemical response
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
She had a good initial biochemical response to therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall.
Summary · context
After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis.
Show in the study text Report a problemFND-3813076901
02HumanCase report or seriesSafety outcome
In a kidney transplant recipient, creatinine rose from 1.17 to 1.69 mg/dL after abaloparatide initiation.
In plain wordsIn a kidney transplant recipient, creatinine rose after abaloparatide began.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCreatinine elevation
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Studied dose
80 μg daily · subcutaneous · 5 monthsAs given in this study (human).
Measurements
Serum creatinine before elevation
1.17 mg/dL
kidney transplant recipient, before elevation
Serum creatinine at elevation
1.69 mg/dL
kidney transplant recipient, 5 months after abaloparatide initiation
Source sentences
Summary
However, 5 months after abaloparatide initiation she was found to have a new elevation in serum creatinine (1.17 to 1.69 mg/dL) despite stable serum tacrolimus trough levels, and two new human leukocyte antigen (HLA) antibodies (anti-HLA antibodies detected to Cw7 and DP28).
2 context sentences(design, population, supporting numbers)
Summary · context
A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall.
Summary · context
After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis.
Show in the study text Report a problemFND-3813076902
03HumanCase report or seriesSafety outcome
In a kidney transplant recipient, new Cw7 and DP28 HLA antibodies appeared after abaloparatide initiation.
In plain wordsIn a kidney transplant recipient, new HLA antibodies appeared after abaloparatide began.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseNew HLA antibodies
Study
n = 1
Outcome group
Immune response · Immune and inflammation
Studied dose
80 μg daily · subcutaneous · 5 monthsAs given in this study (human).
Source sentences
Summary
However, 5 months after abaloparatide initiation she was found to have a new elevation in serum creatinine (1.17 to 1.69 mg/dL) despite stable serum tacrolimus trough levels, and two new human leukocyte antigen (HLA) antibodies (anti-HLA antibodies detected to Cw7 and DP28).
2 context sentences(design, population, supporting numbers)
Summary · context
A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall.
Summary · context
After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis.
Show in the study text Report a problemFND-3813076903
04HumanCase report or seriesSafety outcome
In a kidney transplant recipient, abaloparatide was stopped because of concern about immunogenicity.
In plain wordsIn a kidney transplant recipient, clinicians stopped abaloparatide because of concern about an immune reaction.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableTreatment discontinuation
Study
n = 1
Outcome group
Adverse events · Whole body
Studied dose
80 μg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
Abaloparatide was stopped due to concern for immunogenicity.
2 context sentences(design, population, supporting numbers)
Summary · context
A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall.
Summary · context
After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis.
Show in the study text Report a problemFND-3813076904
05HumanCase report or seriesSafety outcome
In the abaloparatide-treated kidney transplant recipient, biopsy showed no evidence of rejection.
In plain wordsIn the abaloparatide-treated kidney transplant recipient, biopsy showed no rejection.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableKidney biopsy rejection
Study
n = 1
Outcome group
Adverse events · Kidney and urinary
Studied dose
80 μg daily · subcutaneousAs given in this study (human).
Source sentences
Summary
There was no evidence of rejection on kidney biopsy and she was restabilized on her transplant regimen with a new baseline creatinine of 1.3-1.6 mg/dL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall.
Summary · context
After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis.
Show in the study text Report a problemFND-3813076905
06HumanCase report or seriesSafety outcome
After abaloparatide cessation, the kidney transplant recipient stabilized with baseline creatinine of 1.3-1.6 mg/dL.
In plain wordsAfter abaloparatide stopped, the kidney transplant recipient stabilized with creatinine of 1.3-1.6 mg/dL.
Peptide
Abaloparatide (Tymlos)
Outcome
Not applicableCreatinine after discontinuation
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Studied dose
80 μg daily · subcutaneousAs given in this study (human).
Measurements
New baseline serum creatinine after abaloparatide stopped
1.3 to 1.6 mg/dL
kidney transplant recipient, restabilized
Source sentences
Summary
There was no evidence of rejection on kidney biopsy and she was restabilized on her transplant regimen with a new baseline creatinine of 1.3-1.6 mg/dL.
2 context sentences(design, population, supporting numbers)
Summary · context
A 39-year-old female with a history of kidney transplant presented to the endocrinology clinic for osteoporosis evaluation after sustaining an ankle fracture from a fall.
Summary · context
After an appropriate secondary workup, she was started on abaloparatide 80 μg subcutaneous daily injections for osteoporosis.
Show in the study text Report a problemFND-3813076906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.